Medidata Solutions, Inc. (MDSO) Misses Q1 EPS by 5c
Get Alerts MDSO Hot Sheet
Join SI Premium – FREE
Medidata Solutions, Inc. (NASDAQ: MDSO) reported Q1 EPS of $0.11, $0.05 worse than the analyst estimate of $0.16. Revenue for the quarter came in at $76.6 million versus the consensus estimate of $79.5 million.
Highlights
- Medidata’s customer base grew to 420, with 32 new clients added in the first quarter of 2014, an increase of 88% over the number of new clients added in the first quarter of 2013. Customer growth was realized in all regions and across multiple products.
- 52% of customers had committed to multiple products at the end of the first quarter of 2014, up from 41% at the end of the first quarter of 2013.
- Medidata’s industry-leading CRO program continued to grow, with three new partners added, including a top 5 CRO. Several partners also began using a broader set of applications within the Medidata Clinical Cloud™, including Medidata’s trial management solution for their own work.
- Billings were $90 million in the first quarter of 2014, a 43% increase over the first quarter of 2013.
- Subscription backlog for the remainder of the year as of March 31, 2014 increased to $177 million, an increase of $21 million year over year. Subscription backlog does not include revenues associated with intra-year renewals. Including a minimum of $15 million of revenue associated with remaining intra-year renewals, subscription backlog would have increased to $192 million.
- Medidata's overall revenue retention rate was nearly 100%.
For earnings history and earnings-related data on Medidata Solutions, Inc. (MDSO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
- Cineverse Corp (CNVS) Misses Q1 EPS by 20c; Offers Guidance
- Boston Omaha Corporation (BOC) Misses Q2 EPS by 2c
Create E-mail Alert Related Categories
Earnings, Hot Corp. NewsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share